S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
NASDAQ:BLCM

Bellicum Pharmaceuticals - BLCM Stock Forecast, Price & News

$1.18
-0.06 (-4.84%)
(As of 02/2/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.16
▼
$1.25
50-Day Range
$0.65
▼
$1.48
52-Week Range
$0.60
▼
$2.20
Volume
29,654 shs
Average Volume
67,639 shs
Market Capitalization
$10.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Bellicum Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
323.7% Upside
$5.00 Price Target
Short Interest
Healthy
1.06% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.78mentions of Bellicum Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.54) to ($1.13) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.45 out of 5 stars

See Top Rated MarketRank™ Stocks Here
BLCM stock logo

About Bellicum Pharmaceuticals (NASDAQ:BLCM) Stock

Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX.

Receive BLCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bellicum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

BLCM Stock News Headlines

February 2, 2023 | americanbankingnews.com
Bellicum Pharmaceuticals (NASDAQ:BLCM) Coverage Initiated at StockNews.com
January 31, 2023 | finance.yahoo.com
CORRECTION -- Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 3, 2023 | Investor Place Media (Ad)
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
January 25, 2023 | americanbankingnews.com
Bellicum Pharmaceuticals (NASDAQ:BLCM) Receives New Coverage from Analysts at StockNews.com
January 19, 2023 | finance.yahoo.com
Bellicum Pharmaceuticals to Present Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO 2023 Genitourinary Cancers Symposium
November 13, 2022 | finanznachrichten.de
Bellicum Pharmaceuticals, Inc.: Bellicum Reports Third Quarter 2022 Financial Results and Provides Operational Update
November 10, 2022 | finance.yahoo.com
Bellicum Reports Third Quarter 2022 Financial Results and Provides Operational Update
October 4, 2022 | finance.yahoo.com
Bellicum Pharmaceuticals to Participate in the 2022 Cell & Gene Meeting on the Mesa
February 3, 2023 | Investor Place Media (Ad)
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
September 15, 2022 | seekingalpha.com
BLCM Bellicum Pharmaceuticals, Inc.
September 1, 2022 | finance.yahoo.com
Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
August 25, 2022 | finance.yahoo.com
Bellicum Pharmaceuticals (BLCM) Could Find Support Soon, Here's Why You Should Buy the Stock Now
August 18, 2022 | finance.yahoo.com
Is Immunocore (IMCR) Stock Outpacing Its Medical Peers This Year?
August 11, 2022 | finance.yahoo.com
Bellicum Reports Second Quarter 2022 Financial Results and Provides Operational Update
May 13, 2022 | seekingalpha.com
Bellicum Pharmaceuticals GAAP EPS of -$0.25 beats by $0.42
May 13, 2022 | finance.yahoo.com
Bellicum Reports First Quarter 2022 Financial Results and Provides Operational Update
March 24, 2022 | finance.yahoo.com
Bellicum Reports Fourth Quarter 2021 Financial Results and Provides Operational Update
February 16, 2022 | benzinga.com
Ladenburg Thalmann Initiates Coverage On Bellicum Pharmaceuticals with Buy Rating, Announces Price Target of $5
January 26, 2022 | finance.yahoo.com
Bellicum Pharmaceuticals to Participate in the B. Riley Securities 2022 Virtual Oncology Conference
December 13, 2021 | finance.yahoo.com
Bellicum Regains Compliance with Nasdaq Continued Listing Requirements
December 10, 2021 | finance.yahoo.com
Sumitovant Biopharma Highlights Significant Clinical, Regulatory and Commercial Achievements Across its Portfolio of Companies in the Second Quarter of FY2021
December 7, 2021 | msn.com
Bellicum Secures $35M Via Equity Funding, Posts Interim Data From Early GoCAR-T Cancer Studies
December 6, 2021 | markets.businessinsider.com
Bellicum Reports Positive Interim Data From Phase 1/2 GoCAR-T Trials - Quick Facts
December 6, 2021 | finance.yahoo.com
Bellicum Announces Positive Interim Data from Phase 1/2 GoCAR-T® Studies, Secures $35 Million Private Placement Equity Financing Priced at Market
December 2, 2021 | bizjournals.com
K2 BioLabs hiring, expanding contract research offerings for biotech, pharma startups
November 4, 2021 | finance.yahoo.com
Bellicum Reports Third Quarter 2021 Financial Results and Provides Operational Update
September 3, 2021 | finance.yahoo.com
Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
See More Headlines
Receive BLCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bellicum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

BLCM Company Calendar

Last Earnings
11/10/2022
Today
2/02/2023
Next Earnings (Estimated)
3/23/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BLCM
CUSIP
N/A
CIK
1358403
Web
www.bellicum.com
Phone
(281) 454-3424
Fax
N/A
Employees
7
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.00
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+323.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.50)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-9,700,000.00
Net Margins
N/A
Pretax Margin
-1,082.27%
Return on Equity
-140.56%
Return on Assets
-55.50%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.44
Quick Ratio
5.44

Sales & Book Value

Annual Sales
$6.20 million
Price / Sales
1.64
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.90 per share
Price / Book
0.41

Miscellaneous

Outstanding Shares
8,610,000
Free Float
7,726,000
Market Cap
$10.16 million
Optionable
Optionable
Beta
1.56

Key Executives

  • Richard A. Fair
    President, Chief Executive Officer & Director
  • Jenny Chaplin
    Vice President-Strategic Operations
  • Joseph Howard Senesac
    Senior VP-Technical Operations & Quality
  • J. Henri Bayle
    Vice President-Research
  • Charity Scripture
    Chief Development Officer

Key Competitors

View All Competitors













BLCM Stock - Frequently Asked Questions

Should I buy or sell Bellicum Pharmaceuticals stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bellicum Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BLCM shares.
View BLCM analyst ratings or view top-rated stocks.

What is Bellicum Pharmaceuticals' stock price forecast for 2023?

1 analysts have issued 12 month price targets for Bellicum Pharmaceuticals' shares. Their BLCM share price forecasts range from $5.00 to $5.00. On average, they expect the company's share price to reach $5.00 in the next year. This suggests a possible upside of 323.7% from the stock's current price.
View analysts price targets for BLCM or view top-rated stocks among Wall Street analysts.

How have BLCM shares performed in 2023?

Bellicum Pharmaceuticals' stock was trading at $0.72 at the beginning of the year. Since then, BLCM stock has increased by 63.9% and is now trading at $1.18.
View the best growth stocks for 2023 here.

When is Bellicum Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023.
View our BLCM earnings forecast.

How were Bellicum Pharmaceuticals' earnings last quarter?

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) posted its quarterly earnings results on Thursday, November, 10th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter. The biopharmaceutical company had revenue of $1 million for the quarter.

When did Bellicum Pharmaceuticals' stock split?

Shares of Bellicum Pharmaceuticals reverse split on Thursday, February 6th 2020. The 1-10 reverse split was announced on Wednesday, February 5th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 5th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Bellicum Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bellicum Pharmaceuticals investors own include Arrowhead Pharmaceuticals (ARWR), Alliance Resource Partners (ARLP), AVEO Pharmaceuticals (AVEO), TransEnterix (TRXC), CyberArk Software (CYBR), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Novavax (NVAX), Pfizer (PFE) and Inovio Pharmaceuticals (INO).

When did Bellicum Pharmaceuticals IPO?

(BLCM) raised $101 million in an initial public offering on Thursday, December 18th 2014. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, Citigroup and Piper Jaffray acted as the underwriters for the IPO and Trout Capital was co-manager.

What is Bellicum Pharmaceuticals' stock symbol?

Bellicum Pharmaceuticals trades on the NASDAQ under the ticker symbol "BLCM."

Who are Bellicum Pharmaceuticals' major shareholders?

Bellicum Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends.

How do I buy shares of Bellicum Pharmaceuticals?

Shares of BLCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bellicum Pharmaceuticals' stock price today?

One share of BLCM stock can currently be purchased for approximately $1.18.

How much money does Bellicum Pharmaceuticals make?

Bellicum Pharmaceuticals (NASDAQ:BLCM) has a market capitalization of $10.16 million and generates $6.20 million in revenue each year. The biopharmaceutical company earns $-9,700,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis.

How can I contact Bellicum Pharmaceuticals?

Bellicum Pharmaceuticals' mailing address is 2130 WEST HOLCOMBE BOULEVARD SUITE 800, HOUSTON TX, 77030. The official website for the company is www.bellicum.com. The biopharmaceutical company can be reached via phone at (281) 454-3424 or via email at robert.uhl@westwicke.com.

This page (NASDAQ:BLCM) was last updated on 2/3/2023 by MarketBeat.com Staff